Company Information

  

Address: ATTN: CHIEF FINANCIAL OFFICER
950 WINTER STREET 
City: WALTHAM 
State: MA 
Zip Code: 02451 
Telephone: 617-551-4000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Unless otherwise provided in this report, all references in this report to "we," "us," "Radius," "our company," "our," or the "Company" refer to Radius Health, Inc. and our subsidiaries. Overview We are a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Our lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase 3 development for potential use in the treatment of women with postmenopausal osteoporosis. Our New Drug Application, or NDA, for abaloparatide-SC is under regulatory review by the U.S. Food and Drug Administration, or FDA, with a Prescription Drug User Fee Act, or PDUFA, date of March 30, 2017.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2017-4.62NAN/E
12/2016-4.24NAN/E
09/2016-3.81NAN/E
06/2016-3.43NAN/E
03/2016-3.03NAN/E
12/2015-2.56NAN/E
09/2015-1.58NAN/E
06/20153.99NA16.97

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.20Total Liab/Total Assets0.10
Net Inc/Total Assets-0.54Total Liab/Inv Cap0.11
Net Inc/Inv Cap-0.59Total Liab/Comm Equity0.04
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio10.23
Inventory TurnoverNACurrent Ratio10.23
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.98 NA NA 0.00
Cost of Goods Sold 0.11 NA NA 0.00
Selling & Admin Exps 50.12 38.10 27.46 19.24
Operating Income -68.90 -57.63 -53.04 -46.69
Interest Exp NA NA 0.00 0.00
Pretax Income -68.44 -56.94 -52.72 -46.19
Other Income 0.46 0.69 0.32 0.51
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -68.44 -56.94 -52.72 -46.19

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 214.76 282.15 332.49 369.83
Receivables - Total 1.21 NA NA NA
Inventories - Total 1.64 NA NA NA
Total Current Assets 223.55 288.70 334.81 373.49
Net Property, Plant & Equipment 6.74 6.11 4.92 4.06
Total Assets 239.43 295.36 340.28 378.10
Liabilities        
Accounts Payable 31.77 33.00 32.73 25.31
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 31.77 33.00 32.73 25.31
Long-Term Debt NA NA NA NA
Total Liabilities 32.11 33.26 33.10 25.71
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -753.42 -684.99 -628.57 -575.85
Treasury Stock NA NA NA NA
Total Stockholders' Equity 207.32 262.10 307.18 352.39
Total Liabilities and Stockholders' Equity 239.43 295.36 340.28 378.10

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -60.19 -52.76 -36.73 -30.44
Net Cash Provided by Investing Activities 18.44 -34.00 96.60 107.68
Net Cash Provided by Financing Activities 2.23 2.82 0.13 0.77

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-69.13--
12/20130.00-60.69--
12/20140.00-62.48-4.04
12/20150.00-101.53-2.56
12/20160.00-182.80-4.24
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1717648,010--




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.